The Rise of Liquid Biopsy: Market Trends and Insights

Liquid Biopsy Industry Overview

The global liquid biopsy market size was estimated at USD 10.42 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 11.60% from 2024 to 2030. The market for liquid biopsy is witnessing growth due to factors such as the growing prevalence of cancer, technological advancements in cancer diagnostics, and rising preference for minimally invasive cancer diagnostics. Moreover, ongoing research for liquid biopsy assays and tests, aided with the rising adoption and development of multi-cancer early detection tests, provides opportunity for growth of overall market.

With the onset of COVID-19 pandemic, cancer diagnoses were delayed due to reduced diagnostic services and screening programs. Cancer patients are facing many challenges amid the pandemic, such as susceptibility to severe infection and interruption of cancer or usual medical care. The negative impact is likely to be stronger in low- and middle-income countries with poor infrastructure, limited resources, scarcity of medical supplies & personal protective equipment, and shortage of healthcare providers & organized care teams, resulting in a lack of ability to provide & deliver critical care.

Gather more insights about the market drivers, restrains and growth of the Liquid Biopsy Market

For various applications, such as breast, colorectal, ovarian cancer, non-small-cell lung cancer, and prostate cancer, liquid biopsy is used for diagnostics & screening, making it a vital tool. After various studies and speculations, it has been derived that liquid biopsy technique could provide an improved diagnostic outcome. Data suggests the use of screening techniques on high-risk patients who have an ancestral history of cancer. Moreover, over the past several years, studies have shown positive outcomes of liquid biopsy platforms. The government and various regulatory bodies have also shown interest in the area by promoting multiple breakthrough devices for rapid development of the technology.

However, amid the pandemic, several companies have adopted various strategic initiatives for providing safe & easy in-home access for liquid biopsy tests. For instance, in November 2020, NeoGenomics, Inc. announced the launch of a mobile phlebotomy service for liquid biopsy tests, including InvisionFirst and NeoLAB. The company offers its service through two phlebotomy companies, Metro Health Staffing LLC and ExamOne, for broad geographic coverage to ensure tests are performed efficiently.

Key Companies profiled:

• ANGLE plc
• Oncimmune Holdings PLC
• Guardant Health
• Myriad Genetics, Inc.
• Biocept, Inc.
• Lucence Health Inc.
• Freenome Holdings, Inc.
• F. Hoffmann-La Roche Ltd.
• QIAGEN
• Illumina, Inc.
• Thermo Fisher Scientific, Inc.
• Epigenomics AG

Key Liquid Biopsy Company Insights

The presence of pipeline products in the liquid biopsy segment that are expected to launch in the coming years is anticipated to drive the market growth over the forecast period.

• In November 2023, Illumina Inc. announced the new TruSight Oncology 500 ctDNA v2, a new generation of its liquid biopsy assay for genomic profiling.

• In January 2023, Agilent Technologies, Inc. acquired Avida Biomed. This initiative is expected to provide it with rapid growth in the diagnostics and clinical research markets.

Browse through Grand View Research’s Clinical Diagnostics Industry Research Reports.

• The global liver disease diagnostics market size was valued at USD 35.37 billion in 2022 and is anticipated to grow at a CAGR of 6.5% from 2023 to 2030. One of the key factors anticipated to propel the market for liver disease diagnostics is the increasing number of acute and chronic liver illnesses.

• The global cancer diagnostics market size was estimated at USD 107.45 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 6.16% from 2024 to 2030. The growth of this industry is attributed to the growing prevalence of cancer, technological advancements in diagnostics procedures, and rising initiatives undertaken by private and public organizations.

Liquid Biopsy Market Segmentation

Grand View Research has segmented the global liquid biopsy market report based on sample type, biomarker, technology, application, end-use, clinical application, product, and region:

Liquid Biopsy Sample Type Outlook (Revenue, USD Million, 2018 – 2030)

• Blood Sample
• Others

Liquid Biopsy Biomarker Outlook (Revenue, USD Million, 2018 – 2030)

• Circulating Tumor Cells (CTCs)
• Circulating Nucleic Acids
• Exosomes/ Microvesicles
• Circulating Proteins

Liquid Biopsy Technology Outlook (Revenue, USD Million, 2018 – 2030)

• Multi-gene-parallel Analysis (NGS)
• Single Gene Analysis (PCR Microarrays)

Liquid Biopsy Application Outlook (Revenue, USD Million, 2018 – 2030)

• Cancer
• Reproductive Health
o Lung Cancer
o Prostate Cancer
o Breast Cancer
o Colorectal Cancer
o Leukemia
o Gastrointestinal Cancer
o Others
• Others

Liquid Biopsy End-use Outlook (Revenue, USD Million, 2018 – 2030)

• Hospitals and Laboratories
• Specialty Clinics
• Academic and Research Centers
• Others

Liquid Biopsy Clinical Application Outlook (Revenue, USD Million, 2018 – 2030)

• Therapy Selection
• Treatment Monitoring
• Early Cancer Screening
• Recurrence Monitoring
• Others

Liquid Biopsy Product Outlook (Revenue, USD Million, 2018 – 2030)

• Instruments
• Consumables Kits and Reagents
• Software and Services

Liquid Biopsy Regional Outlook (Revenue, USD Million, 2018 – 2030)

• North America
o U.S.
o Canada
• Europe
o Germany
o U.K.
o France
o Italy
o Spain
o Denmark
o Sweden
o Norway
• Asia Pacific
o Japan
o China
o India
o Australia
o South Korea
o Thailand
• Latin America
o Brazil
o Mexico
o Argentina
• Middle East and Africa (MEA)
o South Africa
o Saudi Arabia
o UAE
o Kuwait

Order a free sample PDF of the Liquid Biopsy Market Intelligence Study, published by Grand View Research.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.